Last reviewed · How we verify

IntragamP — Competitive Intelligence Brief

IntragamP (IntragamP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Intravenous immunoglobulin (IVIG). Area: Immunology.

phase 3 Intravenous immunoglobulin (IVIG) Fc receptors, complement system, pathogenic antibodies Immunology Small molecule Live · refreshed every 30 min

Target snapshot

IntragamP (IntragamP) — CSL Limited. IntragamP is an intravenous immunoglobulin (IVIG) preparation that provides passive immunity by delivering pooled human antibodies to modulate immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
IntragamP TARGET IntragamP CSL Limited phase 3 Intravenous immunoglobulin (IVIG) Fc receptors, complement system, pathogenic antibodies
IGSC 20% infusion IGSC 20% infusion Takeda phase 3 Intravenous immunoglobulin (IVIG) Fc receptors, complement system, pathogenic antibodies
Placebo and IVIG Placebo and IVIG The Hospital for Sick Children phase 3 Immunoglobulin replacement therapy / Immunomodulator Multiple (Fc receptors, complement system, pathogenic antibodies)
Gammaplex (5%) Gammaplex (5%) Bio Products Laboratory marketed Intravenous immunoglobulin (IVIG) Fc receptors and complement system (indirect mechanism via antibody delivery)
Asceniv™ Asceniv™ ADMA Biologics, Inc. marketed Intravenous immunoglobulin (IVIG) Polyclonal immunoglobulins (IgG)
IgPro IgPro CSL Behring marketed Intravenous immunoglobulin (IVIG) Multiple pathogenic antigens (polyvalent)
Flebogamma 5% DIF Flebogamma 5% DIF Instituto Grifols, S.A. marketed Intravenous immunoglobulin (IVIG) Fc receptors, pathogenic antigens and antibodies

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Intravenous immunoglobulin (IVIG) class)

  1. CSL Limited · 4 drugs in this class
  2. Instituto Grifols, S.A. · 2 drugs in this class
  3. Bio Products Laboratory · 2 drugs in this class
  4. ADMA Biologics, Inc. · 2 drugs in this class
  5. Grifols Biologicals, LLC · 1 drug in this class
  6. Grifols Therapeutics LLC · 1 drug in this class
  7. Kedrion S.p.A. · 1 drug in this class
  8. Octapharma · 1 drug in this class
  9. Oslo University Hospital · 1 drug in this class
  10. SK Plasma Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). IntragamP — Competitive Intelligence Brief. https://druglandscape.com/ci/intragamp. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: